Kaposi's sarcoma overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
Kaposi's sarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Kaposi's sarcoma overview On the Web |
|
American Roentgen Ray Society Images of Kaposi's sarcoma overview |
|
Risk calculators and risk factors for Kaposi's sarcoma overview |
Overview
Kaposi's sarcoma (KS) is a tumor caused by Human herpesvirus 8 (HHV8), also known as Kaposi's sarcoma-associated herpesvirus (KSHV) . It was originally described by Moritz Kaposi, an Austro-Hungarian dermatologist practicing at the University of Vienna in 1872.[1] It became more widely known as one of the AIDS defining illnesses in the 1980s.
Kaposi’s sarcoma (KS) is a systemic disease that can present with cutaneous lesions with or without internal involvement. Four subtypes have been described: Classic KS, affecting middle aged men of Mediterranean and Jewish descent; African endemic KS; KS in iatrogenically immunosuppressed patients; and AIDS-related KS. The erythematous to violaceous cutaneous lesions seen in KS have several morphologies: macular, patch, plaque, nodular, and exophytic. The cutaneous lesions can be solitary, localized or disseminated. KS can involve the oral cavity, lymph nodes, and viscera. Classic KS tends to be indolent, presenting with erythematous or violaceous patches on the lower extremities. African endemic KS and AIDS-related KS tend to be more aggressive. The AIDS-related KS lesions often rapidly progress to plaques and nodules affecting the upper trunk, face, and oral mucosa. The diagnosis can be made with a tissue biopsy and, if clinically indicated, internal imaging should be done.
Once the diagnosis of KS has been made, treatment is based on the subtype and the presence of localized versus systemic disease. Localized cutaneous disease can be treated with cryotherapy, intralesional injections of vinblastine, alitretinoin gel, radiotherapy, topical immunotherapy (imiquimod), or surgical excision. Extensive cutaneous disease and/or internal disease may require IV chemotherapy and immunotherapy. Discontinuation or reduction of immunosuppressive therapy is recommended when KS arises in the setting of iatrogenic immunosuppression. However, with AIDS-related KS, HAART has been shown to prevent, or induce regression of, KS. Some AIDS patients have complete resolution of the lesions and prolonged remission while continuing the therapy. Therefore, HAART should be considered first-line treatment for these patients, though they may require other concomitant treatments.[2][3][4].
References
- ↑ Kaposi, M (1872). "Idiopathisches multiples Pigmentsarkom der Haut". Arch. Dermatol. Syph. 4: 265–273.
- ↑ Template:Cite doi
- ↑ PMID 16077928 (PMID 16077928)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 20222338 (PMID 20222338)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand